Results 11 to 20 of about 13,819 (183)

Real World Posaconazole Pharmacokinetic Data in Paediatric Stem Cell Transplant Recipients [PDF]

Children
Background: Invasive fungal disease is a significant cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. Posaconazole, a broad-spectrum triazole, is widely used as prophylaxis.
Csaba Kassa, Katalin Csordás, Lídia Hau, Orsolya Horváth, Krisztián Kállay, Gabriella Kertész, Márton Kiss, János Sinkó, Ágnes Wolfort, Gergely Kriván   +9 more
doaj   +2 more sources

Combinations of posaconazole and tacrolimus are effective against infections with azole-resistant Aspergillus fumigatus [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundSolid organ transplant recipients on immunosuppressants such as tacrolimus are at increased risk of developing pulmonary aspergillosis, a severe to deadly complication with limited treatment options, especially against azole-resistant strains ...
Eliane Vanhoffelen, Tine Van Win, Eva Van Braeckel, Eva Van Braeckel, Agustin Reséndiz-Sharpe, Bruno P. A. Cammue, Bruno P. A. Cammue, Katrien Lagrou, Katrien Lagrou, Karin Thevissen, Greetje Vande Velde   +10 more
doaj   +2 more sources

Efficacy and Safety Assessment of Antifungal Prophylaxis with Posaconazole Using Therapeutic Drug Monitoring in Pediatric Patients with Oncohematological Disorders—A Single-Centre Study [PDF]

Journal of Fungi
Introduction: Posaconazole is recommended for prophylaxis in pediatric immunocompromised patients. Due to its variability in bioavailability and drug-to-drug interactions, EBMT recommends regimens based on therapeutic drug monitoring (TDM). Materials and
Karolina Liszka, Paweł Marschollek, Dawid Przystupski, Jowita Frączkiewicz, Monika Mielcarek-Siedziuk, Igor Olejnik, Zuzanna Gamrot, Natalia Haze, Agnieszka Kwella, Paulina Zalewska, Matylda Resztak, Marek Ussowicz, Krzysztof Kałwak   +12 more
doaj   +2 more sources

Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review [PDF]

Frontiers in Pharmacology
BackgroundPosaconazole is a potent antifungal agent widely used to manage invasive fungal infections, especially in immunocompromised individuals.
Ruochen Qu, Ruochen Qu, Yan Liu, Yan Liu, Yan Zhao, Yan Zhao, Ziyi Wang, Ziyi Wang, Shizhao Yuan, Shuai Liu, Jing Yu, Jing Yu   +11 more
doaj   +2 more sources

The effectiveness and safety of posaconazole enteric-coated tablet versus oral suspension in invasive fungal infections [PDF]

Scientific Reports
Posaconazole enteric-coated tablet and oral suspension are two oral drugs in the treatment of invasive fungal infections (IFIs). This study compared the effectiveness and safety between posaconazole enteric-coated tablet and oral suspension, and provided
Yi-Lei Yang, Qiao-Yan Yi, Yi Han, Yan Li, Rui Yang   +4 more
doaj   +2 more sources

Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties [PDF]

Brazilian Journal of Pharmaceutical Sciences, 2022
Posaconazole exerts an extended spectrum of antifungal activity against various strains of clinically relevant moulds and yeasts. In recent years, antifungal triazole posaconazole has become increasingly important for the prophylaxis and treatment of ...
Monika Nijhawan, Monika Godugu, Trapti Saxena, Talat Farheen, Kanchan Dwivedi   +4 more
doaj   +1 more source

Posaconazole in the management of refractory invasive fungal infections

Therapeutics and Clinical Risk Management, 2008
Stefan Langner, Philipp B Staber, Peter NeumeisterDivision of Hematology, Department of Internal Medicine, Medical University of Graz, AustriaAbstract: The rising incidence of invasive fungal infections due to the expanding population of ...
Stefan Langner, Philipp B Staber, Peter Neumeister   +2 more
doaj   +3 more sources

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia

Scientific Reports, 2023
Posaconazole and voriconazole are commonly used for preventing invasive fungal disease (IFD), but few studies compared posaconazole with voriconazole for primary antifungal prophylaxis (PAP) in pediatric acute leukemia.
Songji Tu, Kunlong Zhang, Ningling Wang, Jinhua Chu, Linhai Yang, Zhiwei Xie   +5 more
doaj   +1 more source

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms

Antibiotics, 2022
Candida auris is a potential multidrug-resistant pathogen able to cause biofilm-associated outbreaks, where frequently indwelling devices are the source of infections.
Noémi Balla, Fruzsina Kovács, Bence Balázs, Andrew M. Borman, Aliz Bozó, Ágnes Jakab, Zoltán Tóth, Ola Kobaissi, László Majoros, Renátó Kovács   +9 more
doaj   +1 more source

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients

Blood Science, 2023
Invasive fungal diseases (IFDs) are major and lethal infectious complications for patients with neutropenia after chemotherapy. Prophylaxis with intravenous and oral suspended itraconazole (200 mg Q12h intravenously × 2 days followed by 5 mg/kg·d orally ...
Li Liu, Xiaolei Pei, Runzhi Ma, Yi He, Rongli Zhang, Jialin Wei, Qiaoling Ma, Weihua Zhai, Aiming Pang, Erlie Jiang, Mingzhe Han, Donglin Yang, Sizhou Feng   +12 more
doaj   +1 more source